Get the Weekly Intelligence Brief — top committee picks every Sunday.
TFX · NYSE · STOCK

Teleflex Incorporated

Healthcare Updated August 11, 2026
$133.43
52W $100.18 – $145.00
49/100
$5.91B
-5.7
0.81
AI Committee Verdict
Watch
49/100
Conviction: Contested · 60% agreement · 5 analysts
Contested

Is TFX Bullish or Bearish?

Mixed. Innellis AI committee rates Teleflex Incorporated (TFX) Watch with a composite score of 49/100 , based on 5 analysts with 60% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +11.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -8.75 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -14.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • ROE of only -31.9% -- cheap may mean cheap for a reason — Value
  • Revenue declining -14.5% YoY -- this is not a growth story right now — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
49/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 97%
of 192 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -31.9% -- cheap may mean cheap for a reason
Growth Analyst bearish
15 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -14.5% YoY -- this is not a growth story right now
Technical Analyst neutral
51 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
44.1
Neutral
MACD Histogram
-0.345
Bearish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Support
$121.22
Resistance
$135.07
Bollinger %B
0.38
Inside Bands
Price vs Moving Averages
EMA 9
$135.22 Below
EMA 21
$134.54 Below
EMA 50
$132.25 Above
EMA 200
$126.50 Above

Fundamental Analysis

Valuation
97
Profitability
21
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio -5.7×
P/B Ratio 2.00×
PEG Ratio -0.30
Dividend Yield 1.02%
52W High $145.00
52W Low $100.18
Quality & Growth
ROE -2898.3%
ROA -1303.6%
Gross Margin 5376.5%
Operating Margin 334.9%
Revenue Growth YoY
Debt / Equity 0.99
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -5.7 (inexpensive relative to a 15-40x range); Price-to-book of 2.0x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -29.0%; Return on assets of -13.0%; Net margin of -39.6%; Gross margin of 53.8%; Current ratio of 2.60 (healthy short-term liquidity); Debt-to-equity of 0.99; Free cash flow per share is positive (8.97); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full TFX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore TFX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime